WEBULL
WebtradeDownload

Jiangxi Institute Of Biological Products (SEHK:6915) Stock Price Sinks On Profit Squeeze

Simply Wall St · 1d ago

The market has already marked Jiangxi Institute of Biological Products down, with the stock sliding over 33% across the past month. Yet the real story in these H1 results is the profit squeeze, not the share-price volatility. Basic earnings per share dropped to CN¥0.052749 on revenue of CN¥83.291 million, while the trailing P/E still sits at 43.6x, far above local biotech peers. That mix of softer profitability and rich valuation is exactly where investors need to focus before deciding whether this pullback is overdone or only getting started.

Is Jiangxi Institute of Biological Products now a rare high growth opportunity at a premium multiple, or simply an expensive stock facing a profit squeeze? Compare the current share price against intrinsic value in the valuation analysis for Jiangxi Institute of Biological Products

H1 2026 Earnings Summary

  • Revenue (H1 2026 vs. H1 2025): CN¥83.291 million vs. CN¥99.704 million (decline of about 16.5%)
  • Net Income, Excl. Extra Items (H1 2026 vs. H1 2025): CN¥14.366 million vs. CN¥36.838 million (decline of about 61%)
  • Basic EPS (H1 2026 vs. H1 2025): CN¥0.052749 vs. CN¥0.135362 (decline of about 61%)
  • Trailing Net Profit Margin (Last 12 Months vs. Prior Year): 33% vs. 37.2% (compression of about 4.2 percentage points)

Prefer clean charts over another dense block of earnings tables and ratio math? Get a full visual picture of Jiangxi Institute of Biological Products, with an at a glance view of its valuation in the interactive company report for Jiangxi Institute of Biological Products.

SEHK:6915 Trailing 12-Month Revenue & Expenses Breakdown as at Sep 2026
SEHK:6915 Trailing 12-Month Revenue & Expenses Breakdown as at Sep 2026

Bullish Signals Under Pressure At Jiangxi Institute

Any optimistic read on Jiangxi Institute of Biological Products has to grapple with the sharp step down in earnings quality. Revenue fell about 16.5% while net income excluding extras dropped about 61%, so profitability weakened far faster than sales. That kind of squeeze makes the usual defensive healthcare angle harder to lean on. The business still generates profit and a solid trailing margin of 33%, which points to an underlying franchise with pricing and cost control, but the latest half clearly challenges a straightforward growth or resilience story.

Bearish Concerns Backed By Profit Compression

The more cautious narrative currently has clearer support. Net income excluding extra items declined much faster than revenue, and basic EPS fell roughly 61%, which points to either heavier costs or softer pricing in key product lines. Trailing margin also compressed from 37.2% to 33%, reinforcing that squeeze. With the share price down about 33% over 30 days and roughly 18% across a week, the market appears to be reacting to these pressures rather than ignoring them, even if the company remains profitable.

Compare that profit squeeze against where institutions think SEHK:6915 should trade next. See the consensus price target analysis for Jiangxi Institute of Biological Products

Own Your Next Investing Move

The profit squeeze and rich P/E at Jiangxi Institute of Biological Products make timing crucial, so register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and watch for a better entry point. After you decide to buy or trim a position, manage everything in one place with the Portfolio Command Center that filters routine noise into focused, actionable updates. For longer term decisions, compare your thinking with thousands of investors through the Community so you can see how others are interpreting the same data. By spotting potential catalysts and risks early, you give yourself a better chance of staying ahead of the market rather than reacting to it.

Seeking Fresh Alternatives Beyond Jiangxi Institute

Fresh breakout stories rarely stay under the radar for long. Momentum shifts quickly, information decays, and the best entries get caught early. Scan these ideas and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.